Loading...

Orphazyme A/S

0CUM.L•LSE
HealthcareMedical - Pharmaceuticals
$0.99
$-0.27(-21.25%)

Orphazyme A/S (0CUM.L) Stock Overview

Explore Orphazyme A/S’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for 0CUM.LStats details for 0CUM.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 0CUM.LAnalyst Recommendations details for 0CUM.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative rare diseases. The company offers heat stock proteins that focuses on the treatment of neurodegenerative diseases by harnessing the cell protective properties of the heat shock response, which protects cells from the accumulation of misfolded proteins, aggregated proteins, and dysfunctional lysosomes. Its lead candidate is the Arimoclomol, which is in clinical development for diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, and Inclusion Body Myositis. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

CEO

Mr. Jakob Færch Bendtsen

Employees

1

Headquarters

Ole MaalOees Vej 3, Copenhagen

Founded

2018

Frequently Asked Questions